肺腺癌驱动基因研究相关进展

Advances on Driver Oncogenes of Lung Adenocarcinoma

近来研究证实肺腺癌具有与致癌作用及靶向药物疗效有关的独特分子特征,这些分子改变被视为驱动基因,负责恶性病变的发生和维持。目前发现约50%肺腺癌携带驱动基因,其中EGFR通路起重要作用。本文将对肺腺癌驱动基因的意义及相关研究进行综述。

The adenocarcinoma of the lung has recently shown peculiar molecular characteristics, which relate with both carcinogenesis and response to targeted drugs. Several molecular alterations have been defined as ＂driver oncogenes＂ responsible for both the initiation and maintenance of the malignancy. So far, 50% of lung adenocarcinoma has been found harbouring driver oncogenes, in which epidermal growth factor receptor pathway plays important roles. In this review, we will report mainly the advances on significance of some latest driver mutations.